A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis

BACKGROUND: Patisiran, an RNA interference therapeutic, has demonstrated robust reduction of wild-type and mutant transthyretin protein and was able to improve polyneuropathy and quality of life following 18 months of treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis....

Descripción completa

Detalles Bibliográficos
Autores principales: Coelho, Teresa, Adams, David, Conceição, Isabel, Waddington-Cruz, Márcia, Schmidt, Hartmut H., Buades, Juan, Campistol, Josep, Berk, John L., Polydefkis, Michael, Wang, Jing Jing, Chen, Jihong, Sweetser, Marianne T., Gollob, Jared, Suhr, Ole B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341568/
https://www.ncbi.nlm.nih.gov/pubmed/32641071
http://dx.doi.org/10.1186/s13023-020-01399-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7341568/
https://www.ncbi.nlm.nih.gov/pubmed/32641071
http://dx.doi.org/10.1186/s13023-020-01399-4

Ejemplares similares